Glyconics, which is part of the Deepbridge Life Sciences EIS portfolio, has been awarded an £85,000 Phase 1 grant from the Global Challenges Research Fund (GCRF) to explore the feasibility of implementing a novel low-cost point-of-care diagnostic platform for diabetic screening in developing countries.

The aim of this project is to help tackle diabetes in developing countries as early detection to this problem is key to long-term management of the condition and increased life expectancy.

Dr Kam Pooni, CEO of Glyconics commented;

“We are thrilled, firstly, to have received this GCRF grant which is enabling us to work on this very important project – and, secondly, to be working with key partners so that we can understand how best to introduce our technology into developing countries.”

To find out more about Glyconics please click here.